AIM Vaccine (HKG:6660) said it applied for marketing registration for its 13-valent pneumonia conjugate vaccine with the National Medical Products Administration (NMPA) after its phase-III clinical trials were completed, according to a Friday filing with the Hong Kong bourse.
The results of the Phase III clinical trials were completed unblinding. The vaccine has good immunogenicity and safety and met the pre-defined clinical objectives, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.